title: Dexanabinol prevents development of vasospasm in the rat femoral artery model.
abstract: We postulated that a multi-potential agent such as dexanabinol may prevent the development of vasospasm after subarachnoid hemorrhage. We tested the effect of dexanabinol (10 mg/kg) on established vasospasm in a rat femoral artery model. Dexanabinol was given as single or repeated doses. On the 7th day after blood application, vessels were prepared for transmission electron microscopy studies, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling staining, and studying vessel morphology including luminal area and wall thickness. Application of blood to femoral artery caused a significant narrowing of luminal area (p<0.001) and a marked increase of radial wall thickness (p<0.001) when compared to controls. Similar to its single injection, repeated doses of dexanabinol markedly widened luminal area (p<0.001) near to control values (p>0.05) and decreased radial wall thickness significantly compared to hemorrhage (p<0.05) and vehicle-treated groups (for single p<0.05 and repetitive injections p<0.01). Both single and multiple dexanabinol injections also lowered apoptotic index (p<0.001). In conclusion, dexanabinol seems to prevent established vasospasm and endothelial cell apoptosis.
authors.affiliation: Deparment of Neurosurgery, Eskişehir Osmangazi University School of Medicine, 26080 Eskişehir, Turkey. rdurmaz@ogu.edu.tr
authors.forename: Ramazan
authors.initials: R
authors.lastname: Durmaz
authors.forename: Ahmet
authors.initials: A
authors.lastname: Ozsandik
authors.forename: Varol
authors.initials: V
authors.lastname: Sahintürk
authors.forename: Kismet
authors.initials: K
authors.lastname: Civi
authors.forename: Cengiz
authors.initials: C
authors.lastname: Bayçu
authors.forename: Hilmi
authors.initials: H
authors.lastname: Ozden
authors.forename: Amselem
authors.initials: A
authors.lastname: Shimon
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D005263:Femoral Artery / Q000473:pathology / Q000502:physiology*; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D007962:Leukocytes / Q000473:pathology; D008297:Male; D046529:Microscopy, Electron, Transmission; D009410:Nerve Degeneration / Q000473:pathology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D020206:Subarachnoid Hemorrhage, Traumatic / Q000150:complications / Q000473:pathology; D020301:Vasospasm, Intracranial / Q000209:etiology / Q000517:prevention & control*
chemical_list: D018696:Neuroprotective Agents; D013759:Dronabinol; C062018:HU 211